Form 4 for TXG 10x Genomics, Inc.
Accepted 2026-09-11 16:47:39 ET · period of report 2026-09-09 · accession 0001610717-26-000414 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-11 16:47 | 2026-09-09 | TXG | Taich Adam | CFO | S - Sale | $64.57 | -46.4K | 316.3K | -13% | -$3.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-09-09 | S | D | 1,206 | $63.68 | 361,526 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026. (F2) This transaction was executed in multiple trades at prices ranging from $63.67 to $63.83, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Class A Common Stock | 2026-09-09 | S | D | 31,428 | $64.31 | 330,098 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026. (F3) This transaction was executed in multiple trades at prices ranging from $64.01 to $64.87, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Common | Class A Common Stock | 2026-09-09 | S | D | 13,754 | $65.26 | 316,344 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026. (F4) This transaction was executed in multiple trades at prices ranging from $64.88 to $65.875, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |